Administration of New Oral Treatment for Lupus Begins in Phase 2B Study
A new investigational therapy for lupus called ESK-001 has entered Phase 2B study and researchers are administering the oral drug to study participants. ESK-001 inhibits or blocks the tyrosine kinase 2 or TYK2 enzyme, preventing it from triggering inflammation. TYK2 is a critical driver of disease in lupus. In the LUMUS trial, 388 people living with moderate to severe active lupus who test positive for autoantibodies will be administered the therapy or a placebo for 48 weeks. The group’s overall disease activity will be assessed post-study to determine if the drug reduces flare activity. Continue to follow the Lupus Foundation of America for updates on ESK-001 as well as other lupus clinical trials.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.Subscribe Now